Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selectiveprostanoidFPreceptoragonist. Tafluprost acid shows a high affinity for human prostanoidFPreceptor withK_iandEC₅₀values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity forprostanoid EP3 receptor(IC₅₀=67 nM) than for the prostanoidFPreceptor. Tafluprost acid can be used in the research of glaucoma^[1][2][3].

Tafluprost acid (10, 100 nM, added on days 0 and 2) significantly inhibits adipogenesis in the early and late stages of differentiation of 3T3-L1 preadipocytes^[2].
Tafluprost acid (100 nM, added on day 2 after initiating differentiation) suppresses adipogenesis in wild-type but not in FP knockout mouse primary adipocytes^[2].
Tafluprost acid (10^-4M, 6 hours) stimulates the proliferation, migration of human umbilical vascular endothelial cells (HUVECs)^[4].
Tafluprost acid (10^-4M, 4-18 hours) stimulates the tube formation of HUVECs^[4].

410.45

C₂₂H₂₈F₂O₅

209860-88-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.